A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Completed · Phase 1 · NCT03595059
Conditions: Advanced Solid Tumors
At a glance
- Research payments reported, 2025
- $124,060
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 168
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-155 (drug), Paclitaxel (drug), Docetaxel (drug)
- Dates
- Started 2018-07-13; completion 2025-09-12
- Results posted
- Not yet
An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b). In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory (R/R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enrol…
From ClinicalTrials.gov, last updated 2025-12-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $124,060 in research payments for this study in 2025 (28 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- Patricia M. Lorusso, DO Medical Oncology · Detroit, MI
- Raid M. Aljumaily, M.D. Hematology & Oncology · Greenville, NC
- John D. Powderly II, M.D. Hematology & Oncology · Huntersville, NC
- Jeannine A. Villella, D.O. Gynecologic Oncology · New York, NY
- Marcia R. Cruz-correa, MD Gastroenterology · Rio Piedras, PR
- Monica M. Mita, MD Medical Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University School of Medicine $57,188
- Feinstein Institute for Medical Research $32,503
- Cedars-Sinai Medical Center, CA $12,597
- Sarah Cannon Research Institute LLC $9,296
- Pan American Center for Oncology Trials LLC $5,506
- Carolina Biooncology Institute $3,500
- Adventhealth Orlando, FL $3,471
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.